{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:55:16Z","timestamp":1787993716226,"version":"build-2784847793"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1038\/s41379-021-00999-0","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T08:02:57Z","timestamp":1640678577000},"page":"895-902","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing"],"prefix":"10.1016","volume":"35","author":[{"given":"Donna C.","family":"Ferguson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7714-370X","authenticated-orcid":false,"given":"Amir","family":"Momeni Boroujeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinita S.","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan L.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Arcila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dara S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4905-8946","authenticated-orcid":false,"given":"Snjezana","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-021-00999-0_bib1","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/PAS.0000000000000410","article-title":"Molecular characterization of apocrine salivary duct carcinoma","volume":"39","author":"Chiosea","year":"2015","journal-title":"Am. J. Surg. Pathol"},{"key":"10.1038\/s41379-021-00999-0_bib2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.critrevonc.2009.10.004","article-title":"Major and minor salivary gland tumors","volume":"74","author":"Guzzo","year":"2010","journal-title":"Crit. Rev. Oncol. Hematol"},{"key":"10.1038\/s41379-021-00999-0_bib3","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1158\/1078-0432.CCR-09-0238","article-title":"Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance","volume":"16","author":"Williams","year":"2010","journal-title":"Clin. Cancer Res"},{"key":"10.1038\/s41379-021-00999-0_bib7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.humpath.2019.03.004","article-title":"The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement","volume":"88","author":"Dogan","year":"2019","journal-title":"Hum. Pathol"},{"key":"10.1038\/s41379-021-00999-0_bib8","doi-asserted-by":"crossref","first-page":"996","DOI":"10.2967\/jnumed.115.169540","article-title":"Targeting the human epidermal growth factor receptors with immuno-PET: imaging biomarkers from bench to bedside","volume":"57","author":"Kramer-Marek","year":"2016","journal-title":"J. Nucl. Med"},{"key":"10.1038\/s41379-021-00999-0_bib9","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1200\/JCO.2008.16.2578","article-title":"Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer","volume":"26","author":"Di Leo","year":"2008","journal-title":"J. Clin. Oncol"},{"key":"10.1038\/s41379-021-00999-0_bib10","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1158\/0008-5472.CAN-05-1182","article-title":"Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells","volume":"66","author":"Konecny","year":"2006","journal-title":"Cancer Res"},{"key":"10.1038\/s41379-021-00999-0_bib11","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","volume":"26","author":"Seidman","year":"2008","journal-title":"J. Clin. Oncol"},{"key":"10.1038\/s41379-021-00999-0_bib12","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1158\/1078-0432.CCR-16-0637","article-title":"Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer","volume":"22","author":"Dalin","year":"2016","journal-title":"Clin. Cancer Res"},{"key":"10.1038\/s41379-021-00999-0_bib13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2559.2012.04252.x","article-title":"Salivary duct carcinomas can be classified into luminal androgen receptor\u2010positive, HER2 and basal\u2010like phenotypes","volume":"61","author":"Di Palma","year":"2012","journal-title":"Histopathology"},{"key":"10.1038\/s41379-021-00999-0_bib14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/PAS.0000000000000413","article-title":"Salivary duct carcinoma: the predominance of apocrine morphology, prevalence of histologic variants, and androgen receptor expression","volume":"39","author":"Williams","year":"2015","journal-title":"Am. J. Surg. Pathol"},{"key":"10.1038\/s41379-021-00999-0_bib15","doi-asserted-by":"crossref","unstructured":"Bergamini C., Cavalieri S., Sanguineti G., Farneti A., Licitra L. Treatment of HER2+ metastatic salivary ductal carcinoma in a pregnant woman: a case report. Oxf Med Case Reports 2019, omz102. eCollection (2019)","DOI":"10.1093\/omcr\/omz102"},{"key":"10.1038\/s41379-021-00999-0_bib16","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.oraloncology.2017.06.023","article-title":"Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma","volume":"72","author":"van Boxtel","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1038\/s41379-021-00999-0_bib17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/17843286.2016.1173940","article-title":"Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients","volume":"71","author":"De Block","year":"2016","journal-title":"Acta Clin. Belg"},{"key":"10.1038\/s41379-021-00999-0_bib18","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.1002\/hed.23429","article-title":"Human epidermal receptor 2\u2013amplified salivary duct carcinoma: Regression with dual human epidermal receptor 2 inhibition and anti\u2013vascular endothelial growth factor combination treatment","volume":"36","author":"Falchook","year":"2014","journal-title":"Head Neck"},{"key":"10.1038\/s41379-021-00999-0_bib19","first-page":"111","article-title":"Targeted therapy with trastuzumab for epidermal growth factor receptor 2 (HER2)\u2011positive advanced salivary duct carcinoma: a case report","volume":"11","author":"Gibo","year":"2019","journal-title":"Mol. Clin. Oncol"},{"key":"10.1038\/s41379-021-00999-0_bib20","first-page":"162534","article-title":"Maintenance therapy with trastuzumab in her2 positive metastatic parotid ductal adenocarcinoma","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Case Rep. Oncol. Med"},{"key":"10.1038\/s41379-021-00999-0_bib21","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1159\/000355219","article-title":"Complete response to trastuzumab-based chemotherapy in a patient with human epidermal growth factor receptor-2-positive metastatic salivary duct carcinoma ex pleomorphic adenoma","volume":"6","author":"Kadowaki","year":"2013","journal-title":"Case Rep. Oncol"},{"key":"10.1038\/s41379-021-00999-0_bib22","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s12032-011-9884-1","article-title":"Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review","volume":"29","author":"Kaidar-Person","year":"2012","journal-title":"Med. Oncol"},{"key":"10.1038\/s41379-021-00999-0_bib23","doi-asserted-by":"crossref","first-page":"E372","DOI":"10.1002\/hed.23307","article-title":"Salivary duct carcinoma responding to trastuzumab\u2010based therapy: case report and review of the literature","volume":"35","author":"Krishnamurthy","year":"2013","journal-title":"Head Neck"},{"key":"10.1038\/s41379-021-00999-0_bib24","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1634\/theoncologist.2012-0369","article-title":"Trastuzumab for the treatment of salivary duct carcinoma","volume":"18","author":"Limaye","year":"2013","journal-title":"Oncologist"},{"key":"10.1038\/s41379-021-00999-0_bib25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.oraloncology.2004.03.002","article-title":"Herceptin plus chemotherapy in relapsed and\/or metastatic salivary gland cancer","volume":"41","author":"Locati","year":"2005","journal-title":"Oral Oncol"},{"key":"10.1038\/s41379-021-00999-0_bib26","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/hed.20614","article-title":"Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy","volume":"29","author":"Nabili","year":"2007","journal-title":"Head Neck"},{"key":"10.1038\/s41379-021-00999-0_bib27","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1017\/S0022215108002314","article-title":"Biological therapy of salivary duct carcinoma","volume":"123","author":"Nashed","year":"2009","journal-title":"J. Laryngol. Otol"},{"key":"10.1038\/s41379-021-00999-0_bib28","doi-asserted-by":"crossref","first-page":"E100","DOI":"10.1002\/hed.25392","article-title":"Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor\u20102 high expressing salivary duct carcinomas","volume":"40","author":"Park","year":"2018","journal-title":"Head Neck"},{"key":"10.1038\/s41379-021-00999-0_bib29","first-page":"2587","article-title":"The role of trastuzumab in the management of salivary ductal carcinomas","volume":"33","author":"Perissinotti","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1038\/s41379-021-00999-0_bib30","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/hed.20714","article-title":"Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy","volume":"30","author":"Prat","year":"2008","journal-title":"Head Neck"},{"key":"10.1038\/s41379-021-00999-0_bib31","doi-asserted-by":"crossref","unstructured":"Swed B. L., Cohen R. B., Aggarwal C. Targeting HER2\/neu oncogene overexpression with ado-trastuzumab emtansine in the treatment of metastatic salivary gland neoplasms: a single-institution experience. JCO Precision Oncol. 3, https:\/\/doi.org\/10.1200\/PO.18.00351 (2019)","DOI":"10.1200\/PO.18.00351"},{"key":"10.1038\/s41379-021-00999-0_bib32","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s13691-016-0247-9","article-title":"Pathological response of salivary duct carcinoma to trastuzumab and docetaxel therapy","volume":"5","author":"Ueki","year":"2016","journal-title":"Int. Cancer Conf. J"},{"key":"10.1038\/s41379-021-00999-0_bib33","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1634\/theoncologist.2019-0841","article-title":"The benefits of adjuvant Trastuzumab for HER\u20102\u2010positive salivary gland cancers","volume":"25","author":"Hanna","year":"2020","journal-title":"Oncologist"},{"key":"10.1038\/s41379-021-00999-0_bib34","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch. Pathol. Lab. Med"},{"key":"10.1038\/s41379-021-00999-0_bib35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J. Mol. Diagn"},{"key":"10.1038\/s41379-021-00999-0_bib36","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jmoldx.2016.09.010","article-title":"Next-generation assessment of human epidermal growth factor receptor 2 (ERBB2) amplification status: clinical validation in the context of a hybrid capture-based, comprehensive solid tumor genomic profiling assay","volume":"19","author":"Ross","year":"2017","journal-title":"J. Mol. Diagn"},{"key":"10.1038\/s41379-021-00999-0_bib37","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat. Med"},{"key":"10.1038\/s41379-021-00999-0_bib38","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1093\/nar\/gkw520","article-title":"FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing","volume":"44","author":"Shen","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1038\/s41379-021-00999-0_bib39","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41379-020-00695-5","article-title":"Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays","volume":"34","author":"Robinson","year":"2021","journal-title":"Mod. Pathol"},{"key":"10.1038\/s41379-021-00999-0_bib40","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/ajcp\/aqz031","article-title":"Detection of ERBB2 amplification by next-generation sequencing predicts HER2 expression in colorectal carcinoma","volume":"152","author":"Cenaj","year":"2019","journal-title":"Am. J. Clin. Pathol"},{"key":"10.1038\/s41379-021-00999-0_bib4","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1288\/00005537-199208000-00013","article-title":"Immunohistochemical study of c\u2010erbB\u20102 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness","volume":"102","author":"Sugano","year":"1992","journal-title":"Laryngoscope"},{"key":"10.1038\/s41379-021-00999-0_bib5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1078\/0344-0338-00136","article-title":"Salivary duct carcinoma-a highly aggressive salivary gland tumor with HER-2\/neu oncoprotein overexpression","volume":"197","author":"Skalova","year":"2001","journal-title":"Pathol-Res. Pract"},{"key":"10.1038\/s41379-021-00999-0_bib6","first-page":"5675","article-title":"Amplification and overexpression of HER-2\/neu in carcinomas of the salivary gland: correlation with poor prognosis","volume":"54","author":"Press","year":"1994","journal-title":"Cancer Res"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41379-021-00999-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-021-00999-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222000783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222000783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-021-00999-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:27:35Z","timestamp":1760228855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222000783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0893395222000783"],"URL":"https:\/\/doi.org\/10.1038\/s41379-021-00999-0","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-021-00999-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}